Event info
Date:29 Jun
Time:17:00 - 18:00
Venue:Online
Contact person
Nicole Mastrell

Nicole Mastrell

Event Manager & PA to CEO

nm@mva.org

+45 6141 8634

Immuno-Oncology Applications of Myeloid-Supportive Humanized Immune System Mice

Humanized immune system (HIS) mice have been widely adopted in immuno-oncology research due to their capability of modeling human immune response to immune-modulating therapeutics. Myeloid cell-supportive HIS mice are proving to be invaluable for advancing immuno-oncology applications and extending immunotherapeutic efficacy trials beyond T cells to other immune cells for discovering the next cancer breakthrough.

Myeloid cells are being targeted for immuno-oncology research due to the important role they play in the innate immune response and because of their ability to serve immune regulatory functions. HIS mice which support the development of human myeloid cells can be used to explore new therapeutic mechanisms focused on the manipulation of immune cells, including monocyte and granulocyte lineages: macrophages, dendritic cells, mast cells, basophils, eosinophils, and neutrophils.

Register for the webinar to hear from Ivan Gladwyn-Ng (B.Sc.(Med.), PhD, a Taconic Field Application Scientist, about how myeloid-supporting HIS mice can be applied to investigate different mechanistic strategies for immunotherapy involving myeloid cells, including immune checkpoint inhibition, cancer vaccines, adoptive cell transfer, and more.

Date: Tuesday, June 29, 2021
Time: 17:00 CEST / 11 a.m. ET
Venue: Online

 

READ MORE & SIGN UP

 

Attendees will learn how:

  • Following tumor implantation in HIS mice, human immune cells of both lymphoid and myeloid lineages infiltrate tumors, making the study of specific tumor-infiltrating lymphocyte types possible.
  • HIS mice cells enable the study of human tumor influence on the specific intratumoral immune cell composition (lymphocytes, macrophages, granulocytes).
  • HIS mice containing both human lymphoid and myeloid lineages can be used to study the mechanisms of combination therapies targeting PD-1 and LAG3 as a strategy to improve response to anti-PD-1 drugs.
  • Certain myeloid-supportive HIS mice promote the development of plasmacytoid dendritic cells, a rare human cell type, which play a role in regulating the immunosuppressive functions of Tregs.
  • Myeloid-supportive HIS mice can be applied to new aspects of immunotherapy development.

 

Organized by: